TCR β chain–directed bispecific antibodies for the treatment of T cell cancers-Reference-Cited by-同舟云学术

TCR β chain–directed bispecific antibodies for the treatment of T cell cancers

Published:2021-03-10 Issue:584 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Paul Suman¹²³^ORCID,Pearlman Alexander H.²³^ORCID,Douglass Jacqueline²³^ORCID,Mog Brian J.²³⁴^ORCID,Hsiue Emily Han-Chung²³^ORCID,Hwang Michael S.²³,DiNapoli Sarah R.²³^ORCID,Konig Maximilian F.²³⁵^ORCID,Brown Patrick A.⁶^ORCID,Wright Katharine M.⁷^ORCID,Sur Surojit²³,Gabelli Sandra B.¹⁷⁸^ORCID,Li Yana⁷^ORCID,Ghiaur Gabriel⁹^ORCID,Pardoll Drew M.¹¹⁰^ORCID,Papadopoulos Nickolas¹³^ORCID,Bettegowda Chetan³¹¹^ORCID,Kinzler Kenneth W.¹³¹⁰^ORCID,Zhou Shibin¹³¹⁰^ORCID,Vogelstein Bert¹²³¹⁰^ORCID

Affiliation:

1. Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

2. Howard Hughes Medical Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

3. Ludwig Center and Lustgarten Laboratory, at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

4. Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD 21287, USA.

5. Division of Rheumatology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

6. Division of Pediatric Oncology, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

7. Department of Biophysics and Biophysical Chemistry, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

8. Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

9. Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

10. Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

11. Department of Neurosurgery, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.

Abstract

Bispecific antibodies directed against T cell receptor β chains promote killing of human T cell cancers while preserving most healthy T cells.

Funder

National Institutes of Health

Virginia and D.K. Ludwig Fund for Cancer Research

Lustgarten Foundation for Pancreatic Cancer Research

National Institutes of Health T32 grant

The Commonwealth Fund

National Institutes of Health Cancer Center Support Grant

Bloomberg-Kimmel Institute for Cancer Immunotherapy